Blossom Health & Wellness Clinic - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 114a E Providence Rd, Yeadon, PA 19050 Phone: 267-494-9218 |
Tiff Counseling Services Counselor - Professional Medicare: Not Enrolled in Medicare Practice Location: 703 Longacre Ct, Yeadon, PA 19050 Phone: 484-463-7376 |
United Family Inclusive Living Center Ufil Inc Community/Behavioral Health Agency Medicare: Not Enrolled in Medicare Practice Location: 817 Laurel Rd, Yeadon, PA 19050 Phone: 610-806-5177 |
Motina Services Community/Behavioral Health Agency Medicare: Not Enrolled in Medicare Practice Location: 437 Orchard Ave, Yeadon, PA 19050 Phone: 267-949-6789 Fax: 215-310-4956 |
Pennsylvania Autism Service Clinic - Adolescent and Children Mental Health Medicare: Not Enrolled in Medicare Practice Location: 651 Parkview Blvd, Yeadon, PA 19050 Phone: 215-900-6370 |
News Archive
A group of researchers from EPFL's Global Health Institute (GHI) and Inserm (Institut National de la Sant- et de la Recherche M-dicale, the French government agency for biomedical research) has discovered that a class of chemotherapy drugs originally designed to inhibit key signaling pathways in cancer cells also kills the parasite that causes malaria. The discovery could quickly open up a whole new strategy for combating this deadly disease.
The incidence of premature babies has been stable or even increased over time. The phenomenon brings with it the possibility of neurological, sensorial, respiratory, cognitive or psychomotor consequences for the child, both in the short and the medium term. These consequences also are a concern to child psychiatrists and psychologists, as it is currently known that the progress of a premature baby and the appearance or otherwise of problems depend largely on the family environment, above all how the mother interacts with her child in the first months of its life.
For military veterans suffering from post-traumatic stress disorder (PTSD), symptoms such as anxiety, anger and depression can have a devastating impact on their health, daily routine, relationships and overall quality of life.
Compandia has announced a name change to CompanDX. The company is a biomarker discovery company providing services to the Pharma and Biotech sectors but increasingly, as a result of in-house R&D, is identifying biomarkers that may lead to new diagnostic services and products of its own. Andy Sutton CEO of CompanDX explained "we have grown the service side of the business over the last 9 months and are delivering biomarker discovery services to large pharma, small biotech and diagnostic companies.
About 50% of people who take the drug infliximab for inflammatory bowel diseases, such as Crohn's disease, end up becoming resistant or unresponsive to it.
› Verified 5 days ago